Insulin growth factor-1 protects against excitotoxicity in the rat striatum.
Recent findings demonstrated the neuroprotective effects of insulin-like growth factor 1 (IGF-1) in a cultured cell model of Huntington's disease. In the present study, we examined the potential neuroprotective effect of IGF-1 in vivo, in a rat model of Huntington's disease using the NMDA receptor agonist quinolinate. Continuous intracerebroventricular infusion of recombinant IGF-1 (0.25 microg/h for 2 days) in the rat brain, produced a significant 8-fold increase in striatal levels of the growth factor. Histological evaluation after intrastriatal injection of quinolinate showed that IGF-1 treatment significantly attenuated striatal degeneration. These results further support the therapeutic interest of IGF-1 in Huntington's disease.
Escartin
Carole
C
Unité de Recherche Associée 2210 Commissariat à l'Energie Atomique-Centre National de la Recherche Scientifique, and Program ImaGene, Direction des Sciences du Vivant, 4 place du Général Leclerc, 91401 Cedex, Orsay, France.
Boyer
Frédéric
F
Bemelmans
Alexis-Pierre
AP
Hantraye
Philippe
P
Brouillet
Emmanuel
E
D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity*; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis / Q000494:pharmacology*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D017378:Quinolinic Acid / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley
D018690:Excitatory Amino Acid Agonists; D018696:Neuroprotective Agents; D007334:Insulin-Like Growth Factor I; D017378:Quinolinic Acid